

Express Mail Label EK674916039US  
Date of Deposit: November 6, 2000

11-07-00

#3 GP/165  
12/27/02

PATENT

Attorney Docket No: 15966-539 CIP (CURA-39 CIP)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ART UNIT: 1655  
APPLICANTS: Rothberg, et al.  
SERIAL NO: 09/614,505  
FILING DATE: July 11, 2000  
FOR : METHOD FOR IDENTIFYING A BIOMOLECULE

RECEIVED

NOV 14 2000

TECH CENTER 1600/2900

November 6, 2000  
Boston, Massachusetts

Assistant Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER

Sir:

Transmitted herewith for filing in the present application are the following documents:

- ☒ Information Disclosure Statement (4 pages);
- ☒ Modified Form 1449/PTO (1 page in duplicate);
- ☒ Copies of References Cited, A1-A3, C1-C21;
- ☒ Return Postcard.

No fees are believed to be due in connection with this submission. However, the Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311 (Reference No. 15966-539 (CURA-39 CIP)). A duplicate copy of this transmittal letter is enclosed.


RECEIVED

NOV 14 2000

TECH CENTER 1600/2000

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at (617) 542-6000, Boston, Massachusetts.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529  
Christina V. Karnakis, Reg. No. 45,899  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

TRADOCs:1394907.1(TWBF01!.DOC)

Express Mail Label No.: E 74916039US  
Date of Deposit: November 6, 2000

#3



PATENT

Attorney Docket No: 15966-539 CIP (CURA-39 CIP)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

ART UNIT: 1655  
APPLICANTS: Rothberg, et al.  
SERIAL NO: 09/614,505  
FILING DATE: July 11, 2000  
FOR : METHOD FOR IDENTIFYING A BIOMOLECULE

---

November 6, 2000  
Boston, Massachusetts

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97, and 1.98, Applicant hereby makes of record the attached documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

**U. S. Patents:**

 A1	5,565,340	10/15/96	Chenchik, et al.
A2	5,597,713	1/28/97	Kato, et al.
A3	5,871,697	2/16/99	Rothberg, et al.



4/11/01

**Other Documents:**

- jc C1 Adams, M. D., et al. (1991). "Complementary DNA sequencing: expressed sequence tags and human genome project." Science 252(5013): 1651-56.
- C2 Banerjee, A. K. (1980). "5'-terminal cap structure in eucaryotic messenger ribonucleic acids." Microbiol Rev 44(2): 175-205.
- C3 Belyavsky, A., et al. (1989). "PCR-based cDNA library construction: general cDNA libraries at the level of a few cells [published erratum appears in Nucleic Acids Res 1989 Jul 25;17(14):5883]." Nucleic Acids Res 17(8): 2919-32.
- C4 Berger, S. L. (1987). "Preparation and characterization of RNA: overview." Methods Enzymol 152: 215-19.
- C5 Bochnig, P., et al. (1987). "A monoclonal antibody against 2.2.7-trimethylguanosine that reacts with intact, class U, small nuclear ribonucleoproteins as well as 7-methylguanosine-capped RNAs." Eur. J. Biochem. 68: 461-467.
- C6 Carninci, P., et al. (1996). "High-efficiency full-length cDNA cloning by biotinylated CAP trapper." Genomics 37(3): 327-36.
- C7 Delort, J., et al. (1989). "An efficient strategy for cloning 5' extremities of rare transcripts permits isolation of multiple 5'-untranslated regions of rat tryptophan hydroxylase mRNA." Nucleic Acids Res 17(16): 6439-48.
- C8 Edery, I., et al. (1995). "An efficient strategy to isolate full-length cDNAs based on an mRNA cap retention procedure (CAPture)." Mol Cell Biol 15(6): 3363-71.
- C9 Frohman, M. A., et al. (1988). "Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer." Proc Natl Acad Sci U S A 85(23): 8998-9002.
- C10 Fromont-Racine, et al. (1993). "A highly sensitive method for mapping the 5' termini of mRNAs." Nucleic Acids Res 21(7): 1683-84.
- C11 Furuichi, Y., et al. (1975). "A blocked structure at the 5' terminus of mRNA from cytoplasmic polyhedrosis virus." Nature 253(5490): 374-75.
- C12 Gubler, U. and B. J. Hoffman (1983). "A simple and very efficient method for generating cDNA libraries." Gene 25(2-3): 263-69.
- C13 Loh, E. Y., J. F. Elliott, et al. (1989). "Polymerase chain reaction with single-sided specificity: analysis of T cell receptor delta chain." Science 243(4888): 217-20.
- C14 Maruyama, K. and S. Sugano (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides." Gene 138(1-2): 171-74.
- C15 Mathieu-Daude, F., et al. (1996). "DNA rehybridization during PCR: the 'C<sub>0</sub>t effect' and its consequences." Nucleic Acids Res 24(11): 2080-86.
- jc C16 Ohara, O., et al. (1989). "One-sided polymerase chain reaction: the amplification of cDNA." Proc Natl
- jjk

APPLICANTS:  
U.S.S.N.:

Rothberg,  
09/614,505

*ja* Acad Sci U S A 86(15): 5673-77.

*ja* C17 Okayama and Berg (1982). Mol. & Cell Biol. 2: 161-70.

*ja* C18 Patanjali, S. R., et al. (1991). "Construction of a uniform-abundance (normalized) cDNA library [published erratum appears in Proc Natl Acad Sci U S A 1991 Jun 1;88(11):5066]." Proc Natl Acad Sci USA 88(5): 1943-47.

*ja* C19 Shatkin, A. J. (1985). "mRNA cap binding proteins: essential factors for initiating translation." Cell 40(2): 223-24.

*ja* C20 Shimkets, R. A., et al. (1999). "Gene expression analysis by transcript profiling coupled to a gene database query." Nat Biotechnol 17(8): 798-803.

*g* C21 Suzuki, Y., et al. (1997). "Construction and characterization of a full length-enriched and a 5'- end-enriched cDNA library." Gene 200(1-2): 149-56.

- ja* 4/11/01
- ☐ This Information Disclosure Statement is being filed:  
within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97


It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Rothberg, [REDACTED]  
U.S.S.N.: 09/614,505

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 15966-539 CIP (CURA-39 CIP)),

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529  
Christina V. Karnakis, Reg. No. 45,899  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

TRADOCS:1394874.1(TW@\$01!.DOC)